AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10166596 — intervention group
Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 2409
Study 8439024 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms/kg intravenous alfentanil
Number of subjects: 32
Study 8439024 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg intravenous alfentanil
Number of subjects: 32
Study 8439024 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthopedic patients)
Number of subjects: 32
Study 3730521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bromopride 10 mg
Number of subjects: 0
Study 3730521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromopride 20 mg
Number of subjects: 0
Study 3730521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular bromopride 20 mg
Number of subjects: 0
Study 3730521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromopride 10 mg
Number of subjects: 0
Study 3730521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromopride 30 mg
Number of subjects: 0
Study 30221597 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of enteric-coated aspirin
Number of subjects: 19114
Study 30221597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 26806605 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ BNP 10 µg/kg, twice-daily for 12 weeks
Number of subjects: 34
Study 26806605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23733278 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG with 10-0 monofilament nylon sutures (group I)
Number of subjects: 32
Study 23733278 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG with in-situ blood coagulum (group II)
Number of subjects: 32
Study 23733278 — intervention group
Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 32
Study 23733278 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 32
Study 22704398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study 22704398 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 4047
Study 20091934 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of epidural local anesthetics plus intravenous opioids
Number of subjects: 0
Study 20091934 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioids only
Number of subjects: 0
Study 18356603 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (Arm A)
Number of subjects: 86
Study 18356603 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue for 9 weeks, then STI (Arm B)
Number of subjects: 86
Study 18356603 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of IL‐2 while on ART, then STI (Arm C)
Number of subjects: 86
Study 18356603 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 intervention
Number of subjects: 86
Study 16157797 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide 3 times daily
Number of subjects: 122
Study 16157797 — intervention group
Group type: COMPARATOR
Intervention: 0.25% timolol maleate gel-forming solution once daily plus placebo twice daily (control)
Number of subjects: 122
Study 11773507 — intervention group
Group type: EXPERIMENTAL
Intervention: palmolein diet
Number of subjects: 14
Study 11773507 — intervention group
Group type: COMPARATOR
Intervention: oleic acid sunflower oil diet
Number of subjects: 14
Study 9927004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength-training program
Number of subjects: 100
Study 9927004 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 100
Study 7570396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7570396 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic treatment
Number of subjects: 0
Study 2178380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466
Study 2178380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study 444661 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMP (melphalan, cyclophosphamide, and carmustine) with tapering course of prednisone
Number of subjects: 252
Study 444661 — intervention group
Group type: COMPARATOR
Intervention: MP (oral melphalan) with tapering course of prednisone
Number of subjects: 252
Study 444661 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMP (for poor-risk group)
Number of subjects: 252
Study 444661 — intervention group
Group type: COMPARATOR
Intervention: MP (for poor-risk group)
Number of subjects: 252
Study 444661 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMP (for good-risk group)
Number of subjects: 252
Study 444661 — intervention group
Group type: COMPARATOR
Intervention: MP (for good-risk group)
Number of subjects: 252
Study 31166864 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shockwave therapy (ESWT) with standard care
Number of subjects: 0
Study 31166864 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with standard care
Number of subjects: 0
Study 28927211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherus Dural Sealant
Number of subjects: 250
Study 28927211 — intervention group
Group type: COMPARATOR
Intervention: DuraSeal Dural Sealant System
Number of subjects: 250
Study 25339110 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stents (Resolute zotarolimus-eluting or Xience V everolimus-eluting stents)
Number of subjects: 674
Study 24481143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic lithotripsy (PL)
Number of subjects: 133
Study 24481143 — intervention group
Group type: COMPARATOR
Intervention: Holmium: YAG laser lithotripsy (LL)
Number of subjects: 133
Study 22956828 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory memory load
Number of subjects: 0
Study 22956828 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic degradation
Number of subjects: 0
Study 22956828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined highest load and most severe degradation
Number of subjects: 0
Study 22956828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha oscillatory dynamics during stimulus-free delay
Number of subjects: 0
Study 22956828 — intervention group
Group type: EXPERIMENTAL
Intervention: Source localization of alpha power
Number of subjects: 0
Study 19542011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate/higher monounsaturated fat diet
Number of subjects: 30
Study 19542011 — intervention group
Group type: COMPARATOR
Intervention: Higher carbohydrate/lower fat diet
Number of subjects: 30
Study 17679749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (400 mg) administered twice weekly after HD sessions for four weeks
Number of subjects: 34
Study 17679749 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice weekly after HD sessions for four weeks
Number of subjects: 34
Study 15457363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression devices (IPC)
Number of subjects: 120
Study 15457363 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 120
Study 11514042 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroid (Pulmicort Turbuhaler)
Number of subjects: 7240
Study 11514042 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 7240
Study 9271766 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise training at the gas exchange threshold (GET)
Number of subjects: 14
Study 8290741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg nocte
Number of subjects: 28
Study 8290741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3125773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rectal diazepam
Number of subjects: 69
Study 3125773 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral sodium valproate
Number of subjects: 69
Study 3125773 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 69
Study 31135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting lipid levels
Number of subjects: 8270
Study 31135812 — intervention group
Group type: COMPARATOR
Intervention: Fasting lipid levels
Number of subjects: 8270
Study 31135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting lipid levels (primary prevention group)
Number of subjects: 8270
Study 31135812 — intervention group
Group type: COMPARATOR
Intervention: Fasting lipid levels (primary prevention group)
Number of subjects: 8270
Study 31135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting and fasting lipid levels
Number of subjects: 8270
Study 29525281 — intervention group
Group type: EXPERIMENTAL
Intervention: LetiFend® vaccine
Number of subjects: 549
Study 27397444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin C (500 mg) twice daily for 7 days prior to surgery
Number of subjects: 70
Study 27397444 — intervention group
Group type: COMPARATOR
Intervention: Antacid tablet as placebo twice daily for 7 days prior to surgery
Number of subjects: 70
Study 27397444 — intervention group
Group type: COMPARATOR
Intervention: Antacid tablet as placebo
Number of subjects: 70
Study 27397444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin C (500 mg)
Number of subjects: 70
Study 24356524 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest wall strapping (CWS)
Number of subjects: 20
Study 24356524 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted control
Number of subjects: 20
Study 22637204 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoCart
Number of subjects: 30
Study 22637204 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 30
Study 20117571 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro intervention (monthly home visits by a promotora over a 7-month period plus monthly mailed newsletters)
Number of subjects: 811
Study 20117571 — intervention group
Group type: COMPARATOR
Intervention: Macro-only condition
Number of subjects: 811
Study 20117571 — intervention group
Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 811
Study 17573791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal consumed 6 hours prior to bedtime
Number of subjects: 32
Study 17573791 — intervention group
Group type: COMPARATOR
Intervention: Standard meal consumed 2 hours prior to bedtime
Number of subjects: 32
Study 17573791 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening meal
Number of subjects: 32
Study 17573791 — intervention group
Group type: COMPARATOR
Intervention: Early evening meal
Number of subjects: 32
Study 16287956 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diet
Number of subjects: 164
Study 16287956 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fat diet
Number of subjects: 164
Study 16287956 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet
Number of subjects: 164
Study 11889297 — intervention group
Group type: EXPERIMENTAL
Intervention: toward‐lateral‐flexion group (infants)
Number of subjects: 168
Study 11889297 — intervention group
Group type: COMPARATOR
Intervention: away‐lateral‐flexion group (infants)
Number of subjects: 168
Study 11889297 — intervention group
Group type: COMPARATOR
Intervention: away‐turning group (infants)
Number of subjects: 168
Study 11889297 — intervention group
Group type: COMPARATOR
Intervention: toward‐turning group (infants)
Number of subjects: 168
Study 10067011 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management group (induction at 39 weeks, N = 98)
Number of subjects: 194
Study 10067011 — intervention group
Group type: COMPARATOR
Intervention: Expectant group (spontaneous labor onset, N = 96)
Number of subjects: 194
Study 7485045 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 186
Study 7485045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 7485045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 186
Study 7485045 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with Lovastatin
Number of subjects: 186
Study 1967920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 57
Study 1967920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 7011597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous LHRH (100 micrograms)
Number of subjects: 4
Study 31678945 — intervention group
Group type: COMPARATOR
Intervention: Best-practice advice (one session of face-to-face self-management advice delivered by a physiotherapist and up to two optional additional sessions)
Number of subjects: 48
Study 31678945 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive functional exercise (up to six sessions of individual face-to-face physiotherapy)
Number of subjects: 48
Study 31678945 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-practice advice and Progressive functional exercise
Number of subjects: 48
Study 28155048 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific LBP patients
Number of subjects: 483
Study 26175279 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided internal jugular vein (USG) puncture
Number of subjects: 110
Study 26175279 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein blindly (IJB)
Number of subjects: 110
Study 26175279 — intervention group
Group type: COMPARATOR
Intervention: Subclavian vein blindly (SCB)
Number of subjects: 110
Study 23260332 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Training (MT)
Number of subjects: 112
Study 23260332 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 112
Study 23260332 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 112
Study 21483095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month group-based multicomponent cognitive intervention
Number of subjects: 43
Study 21483095 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 43
Study 19556517 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 120
Study 19556517 — intervention group
Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 120
Study 18193496 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-containing regimens
Number of subjects: 715
Study 18193496 — intervention group
Group type: EXPERIMENTAL
Intervention: nonadherent subjects
Number of subjects: 715
Study 18193496 — intervention group
Group type: EXPERIMENTAL
Intervention: missing at least 1 medication dose ever
Number of subjects: 715
Study 18193496 — intervention group
Group type: EXPERIMENTAL
Intervention: missing at least 1 medication dose in the past month
Number of subjects: 715
Study 18193496 — intervention group
Group type: EXPERIMENTAL
Intervention: missing at least 1 medication dose in the past weekend
Number of subjects: 715
Study 18193496 — intervention group
Group type: EXPERIMENTAL
Intervention: lower quality of life (QOL)
Number of subjects: 715
Study 15134179 — intervention group
Group type: EXPERIMENTAL
Intervention: Long ZDV treatment duration for mothers (more than 7.5 weeks)
Number of subjects: 98
Study 15134179 — intervention group
Group type: COMPARATOR
Intervention: Short ZDV treatment duration for mothers (no more than 7.5 weeks)
Number of subjects: 98
Study 15134179 — intervention group
Group type: EXPERIMENTAL
Intervention: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received short treatment
Number of subjects: 98
Study 15134179 — intervention group
Group type: EXPERIMENTAL
Intervention: Short ZDV treatment duration for infants (3 days) when mothers received short treatment
Number of subjects: 98
Study 15134179 — intervention group
Group type: EXPERIMENTAL
Intervention: Long ZDV treatment duration for infants (at least 4 weeks) when mothers received long treatment
Number of subjects: 98
Study 11402637 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat plus patch (5 mg androgen patch with heat-generating patch)
Number of subjects: 6
Study 11402637 — intervention group
Group type: COMPARATOR
Intervention: Patch only (5 mg androgen patch without heat)
Number of subjects: 6
Study 11402637 — intervention group
Group type: COMPARATOR
Intervention: No patch (no testosterone patch)
Number of subjects: 6
Study 9596058 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation and relapse-prevention program including a 20-minute bedside counseling session, a 12-minute video, self-help materials, and follow-up calls
Number of subjects: 2
Study 9596058 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic implementation scenarios of the intervention
Number of subjects: 2
Study 7817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan in olive oil (0.3%)
Number of subjects: 12
Study 7817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan in soy oil (0.3%)
Number of subjects: 12
Study 7817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure soy oil (no triclosan)
Number of subjects: 12
Study 7817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan in sunflower seed oil (0.3%)
Number of subjects: 12
Study 7817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan in PEG (0.15%)
Number of subjects: 12
Study 7817156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan in GLY (0.15%)
Number of subjects: 12
Study 7817156 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 3907331 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bid
Number of subjects: 745
Study 3907331 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg hs
Number of subjects: 745
Study 3907331 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg hs
Number of subjects: 745
Study 3907331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg bid
Number of subjects: 745
Study 3907331 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg hs
Number of subjects: 745
Study 3907331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 31600715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet plus intravenous tranexamic acid
Number of subjects: 0
Study 31600715 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet plus placebo
Number of subjects: 0
Study 30577758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime risk (LTR) of maternal death
Number of subjects: 2917
Study 30577758 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mortality ratio (MMR)
Number of subjects: 2917
Study 26350752 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular assays for mutation status at KRAS, NRAS, BRAF, and PIK3CA
Number of subjects: 97
Study 26350752 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) for pTEN and mismatch repair (MMR) protein expression
Number of subjects: 97
Study 24951164 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + oral cyclophosphamide (RT+C)
Number of subjects: 1100
Study 24951164 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + Tamoxifen (RT+Tam)
Number of subjects: 1100
Study 24951164 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 1100
Study 22230599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) + Visual foam sclerotherapy (VFS)
Number of subjects: 97
Study 22230599 — intervention group
Group type: COMPARATOR
Intervention: Visual foam sclerotherapy (VFS) alone
Number of subjects: 97
Study 20733262 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP-mediated cement just after filling
Number of subjects: 0
Study 20733262 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP-mediated cement aged in MEM30 for 1 week
Number of subjects: 0
Study 20733262 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP-mediated cement aged in MEM30 for 6 weeks
Number of subjects: 0
Study 17660457 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol‐remifentanil)
Number of subjects: 50
Study 17660457 — intervention group
Group type: COMPARATOR
Intervention: BAL (fentanyl‐nitrous oxide‐sevoflurane)
Number of subjects: 50
Study 17572381 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0
Study 17572381 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on a negative social memory
Number of subjects: 0
Study 17572381 — intervention group
Group type: COMPARATOR
Intervention: Monitoring the memory
Number of subjects: 0
Study 17572381 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression attempts in everyday life
Number of subjects: 0
Study 17572381 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression vs. focusing
Number of subjects: 0
Study 15562899 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with lemon-flavored cod liver oil (1 teaspoon per day for children > 1 year; halved for children < 1 year) and a children's multivitamin-mineral supplement containing selenium.
Number of subjects: 94
Study 15562899 — intervention group
Group type: COMPARATOR
Intervention: Medical records control group (no supplementation).
Number of subjects: 94
Study 11123828 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (two or more doses)
Number of subjects: 158
Study 11123828 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (one or fewer doses)
Number of subjects: 158
Study 11123828 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 158
Study 11123828 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (one dose)
Number of subjects: 158
Study 11123828 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (two doses)
Number of subjects: 158
Study 11123828 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (three doses)
Number of subjects: 158
Study 8761138 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/d of PEG 4000 without electrolyte addition
Number of subjects: 16
Study 8761138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1330435 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative strategies for the management of pediatric asthma
Number of subjects: 226
Study 2862081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg prostaglandin E2 (PGE2)
Number of subjects: 293
Study 2862081 — intervention group
Group type: COMPARATOR
Intervention: gel only
Number of subjects: 293